Idorsia
Idorsia Appoints Roland Wandeler Chief Executive Officer
Idorsia announced a leadership change on July 1, 2026. Idorsia appointed Grifols Biopharma president Roland Wandeler CEO, succeeding ad-interim CEO Jean-Paul Clozel, to lead the company’s next phase of growth.
What changed
Roland Wandeler was named Chief Executive Officer. Wandeler will succeed Jean-Paul Clozel, who has served as ad-interim CEO since March 2026 and will continue as Chairman of the Board of Directors.
- Leader: Roland Wandeler
- Role: Chief Executive Officer
- Effective: October 1, 2026
- Announcement date: July 1, 2026
Leadership background
Wandeler is a biopharmaceutical executive with more than 25 years of leadership experience across the United States, Europe, and international markets, and currently serves as President, Biopharma at Grifols. Before Grifols, he held senior leadership roles at Amgen, including Corporate Vice President and General Manager of one of the company’s largest US business units, and previously served as Chief Operating Officer of MorphoSys. He holds a PhD in technical sciences from ETH Zurich and earlier worked as a consultant at The Boston Consulting Group.
The mandate
Gabriel Baertschi, Chair of the Nominating, Governance and Compensation Committee, said Wandeler is well suited to lead Idorsia through its next phase of growth. Chairman Jean-Paul Clozel said the priority is to focus the organization on the activities that drive growth and maximize the impact of its portfolio.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Idorsia leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


